BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

Sometimes the pharmaceutical industry is putting in place barriers to generic makers’ ability to get access to and samples of drugs, according to Scott Gottlieb, commissioner of the US Food and Drug Administration (FDA).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Drug makers’ REMS misuse costs $13.4bn per year: report

6 September 2018 The misuse of federal drug programmes by branded pharmaceutical companies is costing the US healthcare system $13.4 billion per year in lost savings, a report commissioned by a generics trade group has claimed.

Americas

FDA’s Gottlieb launches biosimilars action plan

19 July 2018 The US Food and Drug Administration is not going to play regulatory ‘whack-a-mole’ with companies trying to delay or derail the entry of biosimilar competitors, according to Scott Gottlieb, commissioner of the FDA.

Americas

USFDA to modernise generic review with $37.6m funding

19 June 2018 The US Food and Drug Administration is planning to use new budget funding to modernise generic drug review and promote more widespread use of generics.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

BIO 2018: Gottlieb defends naming drug makers, outlines office efforts

More on this story

Editor's picks

Editor's picks

More features